Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317472 | 0.84 | PTPN11 (0.33) | CHRM2CHRM1CHRM3OPRM1 | |
| SCHEMBL21058505 | 0.82 | CHRM2 (0.32) | CHRM2CHRM1CHRM3 | |
| SCHEMBL2141413 | 0.78 | AVPR1A (0.31) | — | |
| SCHEMBL27669268 | 0.78 | — | — | |
| SCHEMBL344863 | 0.78 | CHRM2 (0.46) | CHRM2CHRM1CHRM3OPRM1 | |
| SCHEMBL1290779 | 0.78 | VNN1 (0.38) | OPRM1 | |
| SCHEMBL16113435 | 0.77 | — | — | |
| SCHEMBL345260 | 0.76 | USP2 (0.46) | CHRM2CHRM1CHRM3 | |
| SCHEMBL18044505 | 0.76 | KMT2A (0.35) | OPRM1 | |
| SCHEMBL346149 | 0.74 | CHRM2 (0.36) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356108-B1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-10-15 | — | — | EP | disclosed |
| US-8716289-B2 | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| EP-2356108-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010055267-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | CHRM2 669/4885CHRM1 308/4885CHRM3 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.